دورية أكاديمية
أعرض في EDS

Tumour Necrosis Factor-α, Chemokines, and Leukocyte Infiltrate Are Biomarkers for Pathology in the Brains of Venezuelan Equine Encephalitis (VEEV)-Infected Mice.

التفاصيل البيبلوغرافية
العنوان: Tumour Necrosis Factor-α, Chemokines, and Leukocyte Infiltrate Are Biomarkers for Pathology in the Brains of Venezuelan Equine Encephalitis (VEEV)-Infected Mice.
المؤلفون: Phelps AL; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., Salguero FJ; UK Health Security Agency, Salisbury SP4 0JG, UK., Hunter L; UK Health Security Agency, Salisbury SP4 0JG, UK., Stoll AL; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., Jenner DC; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., O'Brien LM; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., Williamson ED; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., Lever MS; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK., Laws TR; Defence Science and Technology Laboratory, Salisbury SP4 0JQ, UK.
المصدر: Viruses [Viruses] 2023 May 31; Vol. 15 (6). Date of Electronic Publication: 2023 May 31.
نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Encephalomyelitis, Venezuelan Equine* , Encephalitis Virus, Venezuelan Equine*/physiology, Humans ; Horses ; Mice ; Animals ; Tumor Necrosis Factor-alpha ; Brain ; Inflammation/pathology ; Chemokines ; Leukocytes
مستخلص: Venezuelan equine encephalitis virus (VEEV) is a disease typically confined to South and Central America, whereby human disease is characterised by a transient systemic infection and occasionally severe encephalitis, which is associated with lethality. Using an established mouse model of VEEV infection, the encephalitic aspects of the disease were analysed to identify biomarkers associated with inflammation. Sequential sampling of lethally challenged mice (infected subcutaneously) confirmed a rapid onset systemic infection with subsequent spread to the brain within 24 h of the challenge. Changes in inflammatory biomarkers (TNF-α, CCL-2, and CCL-5) and CD45 + cell counts were found to correlate strongly to pathology (R>0.9) and present previously unproven biomarkers for disease severity in the model, more so than viral titre. The greatest level of pathology was observed within the olfactory bulb and midbrain/thalamus. The virus was distributed throughout the brain/encephalon, often in areas not associated with pathology. The principal component analysis identified five principal factors across two independent experiments, with the first two describing almost half of the data: (1) confirmation of a systemic Th1-biased inflammatory response to VEEV infection, and (2) a clear correlation between specific inflammation of the brain and clinical signs of disease. Targeting strongly associated biomarkers of deleterious inflammation may ameliorate or even eliminate the encephalitic syndrome of this disease.
References: J Exp Med. 2022 Apr 4;219(4):. (PMID: 35297953)
PLoS Pathog. 2019 Dec 2;15(12):e1008157. (PMID: 31790515)
Virulence. 2021 Dec;12(1):430-443. (PMID: 33487119)
MAbs. 2010 Jan-Feb;2(1):3-13. (PMID: 20065636)
PLoS Negl Trop Dis. 2021 Feb 17;15(2):e0009115. (PMID: 33596205)
Lancet. 2022 Jan 08;399(10320):143-151. (PMID: 34800427)
Lancet. 2022 Jul 30;400(10349):359-368. (PMID: 35908569)
PLoS Pathog. 2011 Dec;7(12):e1002452. (PMID: 22241982)
Oncotarget. 2016 Jul 19;7(29):45789-45802. (PMID: 27329584)
J Neuroimmunol. 2017 Jul 15;308:118-130. (PMID: 28501330)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
Vaccine. 2020 Apr 9;38(17):3378-3386. (PMID: 32085953)
Iran J Pharm Res. 2011 Fall;10(4):655-83. (PMID: 24250402)
mBio. 2014 Aug 26;5(5):e01476-14. (PMID: 25161189)
N Engl J Med. 2009 Aug 27;361(9):888-98. (PMID: 19710487)
Viruses. 2019 Nov 13;11(11):. (PMID: 31766138)
J Virol. 2014 Oct;88(20):12077-86. (PMID: 25122801)
Vaccine. 2016 Jun 30;34(31):3607-12. (PMID: 27206386)
J Neuroimmunol. 2000 Sep 22;109(2):132-46. (PMID: 10996215)
J Immunol. 2012 Nov 1;189(9):4213-9. (PMID: 23087426)
Virology. 2011 Jun 5;414(2):146-52. (PMID: 21489591)
Virology. 2012 May 10;426(2):100-5. (PMID: 22341308)
BMC Genomics. 2008 Jun 16;9:289. (PMID: 18558011)
Lancet. 2021 May 01;397(10285):1637-1645. (PMID: 33933206)
ACS Chem Neurosci. 2016 Apr 20;7(4):464-9. (PMID: 27058872)
Nat Rev Drug Discov. 2017 Dec 28;17(1):78. (PMID: 29282366)
Vaccine. 2002 Feb 22;20(11-12):1497-504. (PMID: 11858855)
Annu Rev Entomol. 2004;49:141-74. (PMID: 14651460)
Virol J. 2011 Apr 29;8:197. (PMID: 21529366)
Viruses. 2022 Jul 08;14(7):. (PMID: 35891482)
Vaccine. 2005 Feb 18;23(13):1615-23. (PMID: 15694514)
Viruses. 2019 Dec 12;11(12):. (PMID: 31842327)
Mol Pharmacol. 2007 Oct;72(4):799-809. (PMID: 17622575)
J Neuroinflammation. 2016 Aug 25;13(1):196. (PMID: 27562117)
J Virol. 2010 Dec;84(24):12683-90. (PMID: 20926570)
Prog Growth Factor Res. 1990;2(4):193-205. (PMID: 2151936)
J Neuropathol Exp Neurol. 2007 Jun;66(6):533-44. (PMID: 17549013)
Antiviral Res. 2011 Apr;90(1):1-8. (PMID: 21310183)
Virus Res. 2006 Sep;120(1-2):107-12. (PMID: 16621103)
Biochem Pharmacol. 2021 Oct;192:114690. (PMID: 34274356)
Virol J. 2009 Nov 19;6:206. (PMID: 19925641)
Vaccines (Basel). 2020 Jun 03;8(2):. (PMID: 32503232)
J Interferon Cytokine Res. 2003 Jan;23(1):47-50. (PMID: 12639298)
Vaccine. 2010 Aug 2;28(34):5558-64. (PMID: 20600509)
Vet Pathol. 2010 Sep;47(5):790-805. (PMID: 20551475)
Immunol Rev. 2006 Oct;213:48-65. (PMID: 16972896)
J Virol. 2011 Oct;85(20):10682-90. (PMID: 21849461)
J Gen Virol. 2006 Sep;87(Pt 9):2467-2476. (PMID: 16894184)
Antivir Chem Chemother. 2015 Aug;24(3-4):99-108. (PMID: 27503577)
J Infect Dis. 2011 Aug 1;204(3):348-57. (PMID: 21742832)
Lancet Infect Dis. 2022 Aug;22(8):1210-1220. (PMID: 35568049)
Curr Opin Rheumatol. 2013 May;25(3):391-7. (PMID: 23492738)
Expert Rev Anti Infect Ther. 2019 Dec;17(12):957-967. (PMID: 30626237)
Virology. 2001 Jun 5;284(2):190-202. (PMID: 11384219)
J Virol. 2000 Jun;74(11):5006-15. (PMID: 10799574)
Science. 1967 Dec 8;158(3806):1283-6. (PMID: 6058003)
Viruses. 2022 Jun 02;14(6):. (PMID: 35746681)
فهرسة مساهمة: Keywords: VEEV; alphavirus; chemokines; cytokines; inflammation; leukocytes; mouse; pathology; venezuelan equine encephalitis virus
المشرفين على المادة: 0 (Tumor Necrosis Factor-alpha)
0 (Chemokines)
تواريخ الأحداث: Date Created: 20230628 Date Completed: 20230629 Latest Revision: 20240921
رمز التحديث: 20240921
مُعرف محوري في PubMed: PMC10302690
DOI: 10.3390/v15061307
PMID: 37376607
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4915
DOI:10.3390/v15061307